Novel strategies for managing dyslipidemia

Treatment beyond statins

Hua Ling, Tammy L. Burns, Daniel E. Hilleman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: This article reviews the current status of lipid-lowering drugs and their impact on cardiovascular morbidity and mortality. Because there is compelling evidence to suggest that substantial residual risk persists despite the use of current lipid-lowering treatments, novel strategies for managing dyslipidemia are discussed. Summary: Statins remain the drugs of choice for the treatment of dyslipidemia in patients with coronary heart disease or substantial risk factors for coronary heart disease. The evidence supporting the use of non-statin mono-therapy for reductions in cardiovascular morbidity and mortality is examined. Furthermore, the evidence supporting the use of combinations of lipid-lowering drugs, primarily a statin plus another agent, for reductions in cardiovascular morbidity and mortality is discussed. Available clinical data for novel dyslipidemia drugs that can potentially expand on the current known benefits of statin therapy are reviewed. The cholesteryl ester transfer protein inhibitors, which predominantly increase high-density lipoprotein cholesterol levels and can also substantially lower low-density lipoprotein cholesterol levels, have the most robust clinical trial data, including some phase 3 study results. The proprotein convertase subtilisin/kexin type 9 inhibitors, which predominantly impact low-density lipoprotein cholesterol, are also being tested in phase 3 studies, but their widespread application may be limited by their need to be administered by injection. Peroxisome proliferator-activated receptor (PPAR) agonists with dual agonism of PPAR-α and PPAR-γ to optimize glycemic and lipid profiles may benefit patients with both diabetes and cardiovascular disease. The other novel lipid-lowering drugs are in earlier-phase human testing. Conclusion: Novel agents have the potential to be valuable additions to current treatment of dyslipidemia to reduce cardiovascular morbidity and mortality. These new drugs will not only have to be able to demonstrate an improvement in patients' lipid profiles, but will also have to be able to demonstrate that they reduce cardiovascular morbidity and mortality, typically in combination with statin therapy.

Original languageEnglish
Pages (from-to)43-54
Number of pages12
JournalPostgraduate Medicine
Volume124
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Lipids
Peroxisome Proliferator-Activated Receptors
Morbidity
Mortality
Pharmaceutical Preparations
LDL Cholesterol
Coronary Disease
Therapeutics
Cholesterol Ester Transfer Proteins
HDL Cholesterol
Cardiovascular Diseases
Clinical Trials
Injections

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Novel strategies for managing dyslipidemia : Treatment beyond statins. / Ling, Hua; Burns, Tammy L.; Hilleman, Daniel E.

In: Postgraduate Medicine, Vol. 124, No. 6, 11.2012, p. 43-54.

Research output: Contribution to journalArticle

@article{ae269ac8cad643ab9e407e142ca99fe0,
title = "Novel strategies for managing dyslipidemia: Treatment beyond statins",
abstract = "Purpose: This article reviews the current status of lipid-lowering drugs and their impact on cardiovascular morbidity and mortality. Because there is compelling evidence to suggest that substantial residual risk persists despite the use of current lipid-lowering treatments, novel strategies for managing dyslipidemia are discussed. Summary: Statins remain the drugs of choice for the treatment of dyslipidemia in patients with coronary heart disease or substantial risk factors for coronary heart disease. The evidence supporting the use of non-statin mono-therapy for reductions in cardiovascular morbidity and mortality is examined. Furthermore, the evidence supporting the use of combinations of lipid-lowering drugs, primarily a statin plus another agent, for reductions in cardiovascular morbidity and mortality is discussed. Available clinical data for novel dyslipidemia drugs that can potentially expand on the current known benefits of statin therapy are reviewed. The cholesteryl ester transfer protein inhibitors, which predominantly increase high-density lipoprotein cholesterol levels and can also substantially lower low-density lipoprotein cholesterol levels, have the most robust clinical trial data, including some phase 3 study results. The proprotein convertase subtilisin/kexin type 9 inhibitors, which predominantly impact low-density lipoprotein cholesterol, are also being tested in phase 3 studies, but their widespread application may be limited by their need to be administered by injection. Peroxisome proliferator-activated receptor (PPAR) agonists with dual agonism of PPAR-α and PPAR-γ to optimize glycemic and lipid profiles may benefit patients with both diabetes and cardiovascular disease. The other novel lipid-lowering drugs are in earlier-phase human testing. Conclusion: Novel agents have the potential to be valuable additions to current treatment of dyslipidemia to reduce cardiovascular morbidity and mortality. These new drugs will not only have to be able to demonstrate an improvement in patients' lipid profiles, but will also have to be able to demonstrate that they reduce cardiovascular morbidity and mortality, typically in combination with statin therapy.",
author = "Hua Ling and Burns, {Tammy L.} and Hilleman, {Daniel E.}",
year = "2012",
month = "11",
doi = "10.3810/pgm.2012.11.2612",
language = "English",
volume = "124",
pages = "43--54",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "6",

}

TY - JOUR

T1 - Novel strategies for managing dyslipidemia

T2 - Treatment beyond statins

AU - Ling, Hua

AU - Burns, Tammy L.

AU - Hilleman, Daniel E.

PY - 2012/11

Y1 - 2012/11

N2 - Purpose: This article reviews the current status of lipid-lowering drugs and their impact on cardiovascular morbidity and mortality. Because there is compelling evidence to suggest that substantial residual risk persists despite the use of current lipid-lowering treatments, novel strategies for managing dyslipidemia are discussed. Summary: Statins remain the drugs of choice for the treatment of dyslipidemia in patients with coronary heart disease or substantial risk factors for coronary heart disease. The evidence supporting the use of non-statin mono-therapy for reductions in cardiovascular morbidity and mortality is examined. Furthermore, the evidence supporting the use of combinations of lipid-lowering drugs, primarily a statin plus another agent, for reductions in cardiovascular morbidity and mortality is discussed. Available clinical data for novel dyslipidemia drugs that can potentially expand on the current known benefits of statin therapy are reviewed. The cholesteryl ester transfer protein inhibitors, which predominantly increase high-density lipoprotein cholesterol levels and can also substantially lower low-density lipoprotein cholesterol levels, have the most robust clinical trial data, including some phase 3 study results. The proprotein convertase subtilisin/kexin type 9 inhibitors, which predominantly impact low-density lipoprotein cholesterol, are also being tested in phase 3 studies, but their widespread application may be limited by their need to be administered by injection. Peroxisome proliferator-activated receptor (PPAR) agonists with dual agonism of PPAR-α and PPAR-γ to optimize glycemic and lipid profiles may benefit patients with both diabetes and cardiovascular disease. The other novel lipid-lowering drugs are in earlier-phase human testing. Conclusion: Novel agents have the potential to be valuable additions to current treatment of dyslipidemia to reduce cardiovascular morbidity and mortality. These new drugs will not only have to be able to demonstrate an improvement in patients' lipid profiles, but will also have to be able to demonstrate that they reduce cardiovascular morbidity and mortality, typically in combination with statin therapy.

AB - Purpose: This article reviews the current status of lipid-lowering drugs and their impact on cardiovascular morbidity and mortality. Because there is compelling evidence to suggest that substantial residual risk persists despite the use of current lipid-lowering treatments, novel strategies for managing dyslipidemia are discussed. Summary: Statins remain the drugs of choice for the treatment of dyslipidemia in patients with coronary heart disease or substantial risk factors for coronary heart disease. The evidence supporting the use of non-statin mono-therapy for reductions in cardiovascular morbidity and mortality is examined. Furthermore, the evidence supporting the use of combinations of lipid-lowering drugs, primarily a statin plus another agent, for reductions in cardiovascular morbidity and mortality is discussed. Available clinical data for novel dyslipidemia drugs that can potentially expand on the current known benefits of statin therapy are reviewed. The cholesteryl ester transfer protein inhibitors, which predominantly increase high-density lipoprotein cholesterol levels and can also substantially lower low-density lipoprotein cholesterol levels, have the most robust clinical trial data, including some phase 3 study results. The proprotein convertase subtilisin/kexin type 9 inhibitors, which predominantly impact low-density lipoprotein cholesterol, are also being tested in phase 3 studies, but their widespread application may be limited by their need to be administered by injection. Peroxisome proliferator-activated receptor (PPAR) agonists with dual agonism of PPAR-α and PPAR-γ to optimize glycemic and lipid profiles may benefit patients with both diabetes and cardiovascular disease. The other novel lipid-lowering drugs are in earlier-phase human testing. Conclusion: Novel agents have the potential to be valuable additions to current treatment of dyslipidemia to reduce cardiovascular morbidity and mortality. These new drugs will not only have to be able to demonstrate an improvement in patients' lipid profiles, but will also have to be able to demonstrate that they reduce cardiovascular morbidity and mortality, typically in combination with statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=84875792307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875792307&partnerID=8YFLogxK

U2 - 10.3810/pgm.2012.11.2612

DO - 10.3810/pgm.2012.11.2612

M3 - Article

VL - 124

SP - 43

EP - 54

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 6

ER -